The Eigen Therapeutics team. Front row (L-R): Senior scientist Anukriti Dhar, associate scientist Molly Volkman, CSO Kathryn Vanderlaag. Back row (L-R): Lead engineer Erik Werner, CEO Transon Nguyen, CTO Kamran Ali

December 8, 2022 04:00 AM EST

Startups

Priming therapy biotech emerges from stealth with seed funding — and on a hunt for partners

Katherine Lewin

News Reporter

At Eigen Therapeutics, the goal is to make cancer treatment more effective. But not by making targeted drugs.

With $7 million in seed funding announced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Priming therapy biotech emerges from stealth with seed funding — and on a hunt for partners

Katherine Lewin

News Reporter

Sign up to read this article for free.

Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability

Altos Labs buys anti-aging startup Dorian Therapeutics

Genentech expands deal with molecular glue biotech Orionis for $105M upfront

How PureTech’s lung fibrosis drug stacks up against the competition

Cocaine vaccine, a longshot attempt to quell cravings, yields mixed data in small study

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

Prim­ing ther­a­py biotech emerges from stealth with seed fund­ing — and on a hunt for part­ners

Katherine Lewin

News Reporter

Sign up to read this article for free.

Big leas­es, big­ger re­grets: Biotech slump turns swanky of­fices from as­set in­to li­a­bil­i­ty

Al­tos Labs buys an­ti-ag­ing start­up Do­ri­an Ther­a­peu­tics

Genen­tech ex­pands deal with mol­e­c­u­lar glue biotech Ori­o­n­is for $105M up­front

How PureTech’s lung fi­bro­sis drug stacks up against the com­pe­ti­tion

Co­caine vac­cine, a long­shot at­tempt to quell crav­ings, yields mixed da­ta in small study

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

Priming therapy biotech emerges from stealth with seed funding — and on a hunt for partners

Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability

Altos Labs buys anti-aging startup Dorian Therapeutics

Genentech expands deal with molecular glue biotech Orionis for $105M upfront

How PureTech’s lung fibrosis drug stacks up against the competition

Cocaine vaccine, a longshot attempt to quell cravings, yields mixed data in small study

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?